Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Arrhythmia/Electrophysiology
Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients ― Fushimi AF Registry ―
Yugo YamashitaRyuji UozumiYasuhiro HamataniMasahiro EsatoYeong-Hwa ChunHikari TsujiHiromichi WadaKoji HasegawaHisashi OgawaMitsuru AbeSatoshi MoritaMasaharu Akao
Author information
JOURNALS FREE ACCESS FULL-TEXT HTML

2017 Volume 81 Issue 9 Pages 1278-1285

Details
Abstract

Background:The current status and outcomes of direct oral anticoagulant (DOAC) use have not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world.

Methods and Results:The Fushimi AF Registry is a community-based prospective survey of AF patients who visited the participating medical institutions (n=80) in Fushimi, Kyoto, Japan. Follow-up data with oral anticoagulant (OAC) status were available for 3,731 patients by the end of November 2015. We evaluated OAC status and clinical outcomes according to OAC status. The number (incidence rate) of stroke/systemic embolism (SE) and major bleeding events during the median follow-up of 3.0 years was 224 (2.3%/year) and 177 (1.8%/year), respectively. After the release of DOAC, the prevalence of DOAC use increased gradually and steadily, and that of warfarin, DOAC and no OAC was 37%, 26% and 36%, respectively in 2015. On Cox proportional hazards modeling incorporating change in OAC status as a time-dependent covariate for stroke/SE and major bleeding events, use of DOAC compared with warfarin was not associated with stroke/SE events (HR, 0.95; 95% CI: 0.59–1.51, P=0.82) or major bleeding events (HR, 0.82; 95% CI: 0.50–1.36, P=0.45).

Conclusions:In real-world clinical practice, there were no significant differences in stroke/SE events or major bleeding events for DOAC compared with warfarin in patients with AF.

Information related to the author
© 2017 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top